Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Tuberculosis Elimination Revisited: Obstacles, Opportunities, and a Renewed Commitment -- Advisory Council for the Elimination of Tuberculosis (ACET)
Advisory Council for the Elimination of Tuberculosis (ACET)
Charles M. Nolan, M.D.
David L. Cohn, M.D.
Wafaa M. El-Sadr, M.D., M.P.H.
Kathleen F. Gensheimer, M.D.
L. Masae Kawamura, M.D.
Christina Larkin, M.P.A.
Michael S.A. Richardson, M.D.
Lawrence L. Sanders, Jr., M.D.
Stephanie B.C. Bailey, M.D., M.S.H.S.A.
Charles Edward Wallace, Ph.D, M.P.H.
EX OFFICIO MEMBERS
Amy S. Bloom, M.D.
Michael J. Brennan, Ph.D.
Georgia S. Buggs, M.P.H.
James E. Cheek, M.D.
Amanda L. Edens
Ann M. Ginsberg, M.D., Ph.D.
Warren W. Hewitt, Jr., M.S.
Michael P. Johnson, M.D.
Gary A. Roselle, M.D.
John B. Bass, Jr., M.D.
Fran DuMelle, M.S.
Nancy E. Dunlap, M.D.
Susan W. Forlenza, M.D.
Carol J. Pozsik, M.P.H.
Walter F. Schlech, M.D.
Larry Schlesinger, M.D.
Michael L. Tapper, M.D.
In 1989, CDC and the Advisory Council for the Elimination of Tuberculosis (ACET) issued A Strategic Plan for the Elimination of Tuberculosis in the United States. Since then, the United States has experienced a resurgence of tuberculosis (TB) followed by a successful mobilization against the epidemic. Because the nature of this disease has changed during the past decade, ACET has reassessed its 1989 plan. Recent progress against TB should reinforce the nation's confidence that the disease can be controlled and ultimately eliminated. However, existing TB-control efforts must be sustained and enhanced, and new and improved diagnostic, treatment, and prevention methods, including a new vaccine, must be developed and applied. Support for these efforts should be broad-based and include the establishment of new partnerships. Because eliminating TB in the United States will have widespread economic, public health, and social benefits, committing to this action will also fulfill an obligation to persons throughout the world who have this preventable and curable disease. With this reassessment, ACET reaffirms its call for the elimination of TB in the United States.
In 1989, CDC and the Advisory Council for the Elimination of Tuberculosis (ACET) issued A Strategic Plan for the Elimination of Tuberculosis in the United States (1). This plan established a national goal of tuberculosis (TB) elimination, defined as a case rate of less than 1/1,000,000 population by 2010, with an interim target of 3.5/100,000 population by the year 2000. The plan also described the following actions needed to achieve TB elimination: a) more effective use of existing prevention and control methods, especially among high-risk populations; b) development and evaluation of new technologies for TB diagnosis, treatment, and prevention; and c) rapid transfer of newly developed technologies into clinical and public health practice. For the past 10 years, this plan has provided the framework for the nation's TB-control efforts, including a successful mobilization against the resurgence of TB associated with a) deterioration of the public health infrastructure, b) increasing cases among foreign-born persons, c) human immunodeficiency virus (HIV) infection, and d) transmission of multidrug-resistant TB (MDR TB) in institutional settings (2).
However, TB in the United States has changed during the past decade. Since 1993, TB morbidity has steadily declined, and the disease is more likely to occur in well-defined risk groups and geographic areas that can be targeted for control efforts. But new diagnostic and therapeutic tools are needed to continue the recent progress toward TB elimination (3). In addition, a growing awareness that the worldwide TB epidemic has implications for the United States has led to increased U.S. involvement in the global battle against TB and an initiative to develop an effective vaccine (4,5). Finally, changes in the organization, delivery, and financing of health care have created new challenges for TB elimination (6).
Thus, ACET, which provides advice and recommendations regarding the elimination of TB to the U.S. Department of Health and Human Services and CDC, reassessed its 1989 plan and made updated recommendations for TB elimination. In its reassessment, ACET concluded that the past decade of progress against TB should reinforce the nation's confidence in the following concepts:
The Changing Epidemiology of TB
During 1953-1985, the number of TB cases reported annually in the United States dropped 74%, from 84,304 to 22,201. Subsequently, this trend stopped. In 1989, when CDC issued its TB elimination plan, reported TB cases had increased approximately 5% over the previous year; cases continued to rise, reaching a peak of 26,673 in 1992 (7). This resurgence was associated with a) the HIV epidemic, which substantially increased the risk for active TB among persons with latent TB infection; b) immigration from TB-endemic countries; c) TB transmission in congregate settings (e.g., hospitals and prisons); d) deterioration of the infrastructure for TB services; and e) development of difficult-to-treat cases of MDR TB (8).
Studies conducted during this period of TB resurgence indicated substantial, on-going transmission of TB and development of active TB in many recently infected persons (9,10). This phenomenon appeared to primarily affect certain high-risk populations (e.g., persons who were HIV-infected, homeless, or incarcerated), suggesting the existence of several concurrent TB epidemics in the United States. The resurgence of TB during 1985-1992 was accompanied by an increase in the number of persons with MDR TB, largely because of MDR TB outbreaks among HIV-infected persons in institutional settings (11). The rise in total TB cases, coupled with increased drug resistance, has challenged state and local control efforts (2).
Since 1992, the number of reported TB cases in the United States has decreased each year, reaching a record low of 18,361 in 1998, with a case rate of 6.8/100,000 and an overall decline of 31% (CDC, unpublished data, 1998). This reduction is attributed to more effective TB-control programs that emphasize prompt identification of persons with TB, prompt initiation of appropriate therapy, and efforts to assure that therapy will be completed (12).
The recent success in TB control in the United States is tempered by the burden of TB among foreign-born persons residing in this country. An increasing percentage of U.S. cases are occurring among persons who were born in Asian, African, or Latin American countries, where TB rates are 5-30 times higher than U.S. rates (13). During 1992-1997, the number of TB cases among U.S.-born persons declined 38%, whereas the number of TB cases among foreign-born persons in the United States increased 6%. The TB case rate for foreign-born persons has remained at least 4-5 times higher than that for U.S.-born persons, and the proportion of U.S. cases occurring in foreign-born persons has increased steadily since the mid-1980s, reaching 42% in 1998 (CDC, unpublished data, 1998).
Rebuilding the Public Health Infrastructure
Following the resurgence of TB and the emergence of MDR TB as a public health threat, federal resources were increased to a) strengthen TB surveillance, b) improve laboratory capacity for identifying mycobacterial species and conducting real-time drug susceptibility testing, c) expand the use of directly observed therapy (DOT), and d) expedite investigation of the close contacts of TB patients. The subsequent 31% decrease in annual TB cases during 1992-1998 is a notable public health achievement and a measurable return on the resources invested to strengthen TB-control programs nationwide. Increasing the number of patients who complete TB therapy, including those in hard-to-reach populations, has contributed to these reductions. In many areas, TB screening and preventive therapy services directed toward high-risk groups, especially persons at risk for HIV infection and persons in correctional facilities, have expanded substantially. Surveillance data and research on adherence to treatment have better characterized risk groups, leading to more effective, targeted interventions.
Additionally, training and educational activities and products are increasingly available nationwide for health-care providers. New materials are developed as needed to address the changing TB epidemiology and scientific advances in diagnosis and treatment. ACET has issued several statements on TB-control practices, which are available on the Internet (14). Three model TB centers were established in 1994 as national educational resources to provide TB services, expert consultation, and training for health-care providers. In 1999, these centers worked with CDC to develop the Strategic Plan for Tuberculosis Education and Training to guide efforts in this area during the next 5 years (15).
Despite these efforts, DOT and other measures to improve timely completion of treatment are underused in many areas of the country (16). The investigation of contacts of infectious patients and the treatment of persons with latent TB infection are often inadequate. Although the numbers of cases have again started to decline in some areas, TB continues to be a serious public health threat requiring resources to maintain and enhance recent gains in prevention and control (17).
Changes in Health Care Organization and Delivery
The marked changes in providing and financing health care in the United States during the past decade present both challenges and opportunities for TB control. Approximately 80 million persons in the United States are enrolled in health maintenance organizations (6). Managed care programs serve one third of Medicaid beneficiaries, with enrollment in such programs growing 30%-40% annually (18). Opportunities exist for TB-control programs to work with health-care providers in managed care programs to provide high-quality, preventive TB services to persons at high risk (19). Providing such services could be cost-saving (20). However, the extent to which managed care programs can provide optimal TB surveillance and reporting, as well as treatment and prevention services, is uncertain, especially in regard to the many previously uninsured persons now covered by managed care plans.
Recognition of the Interdependence of Global TB and TB in the United States
Worldwide, approximately 8 million cases and 2 million deaths were attributed to TB in 1998 (21). A close relationship exists between the global TB problem and the impact of the disease in the United States. TB cases among foreign-born persons residing in the United States could soon outnumber cases among U.S.-born persons. Thus, TB elimination in the United States will not be possible without a substantial reduction in the global TB burden. However, global TB-control efforts are hampered by several barriers, including the failure of some developing countries and donor countries to fund effective TB-control programs. The World Health Organization (WHO) estimates that, in 1997, only 32% of the world's population was living in areas where effective TB-control programs were fully implemented and operational (22). In many countries in sub-Saharan Africa, HIV infection has led to the doubling and tripling of TB cases, threatening to overwhelm TB-control programs in these countries (23). None of the strategies for TB control recommended for low-income countries appears to have decreased the number of HIV-associated TB cases. Moreover, MDR TB has emerged as a serious problem in many countries (24). Treatment of MDR TB is expensive and beyond the resources of most developing nations, and increases in MDR TB threaten global TB-control efforts and add urgency to the push for effective interventions worldwide.
WHO has developed a control strategy known as directly observed therapy, short-course (DOTS), which requires microscopy-based diagnosis, standardized treatment under direct supervision, a secure supply of quality drugs and equipment, careful monitoring and supervision, and political commitment to support these activities (25). WHO has advocated for increased assistance from wealthier countries to support DOTS programs that require outside assistance. Other international organizations have joined the call for increased U.S. support for global TB control; as a result, U.S. participation has increased, particularly through the U.S. Agency for International Development (USAID).
An important component of the 1989 TB elimination plan was the call for development of new tools for TB diagnosis, treatment, and prevention. In 1989, Public Health Service support for TB research totaled less than $5 million. With a renewed interest in TB, funding for research has increased. The National Institutes of Health (NIH) spends approximately $60 million/year, and CDC provides approximately $15 million/year. Although this expanded research has not had time to produce breakthroughs, progress has been made.
Since 1989, advances have been made in applied TB diagnostics, including new methods that reduce the time needed to detect growth of Mycobacterium tuberculosis in diagnostic specimens (26). New rapid-detection methods using nucleic acid amplification techniques that provide results within hours have been licensed for use in the United States (27). Rapid methods to identify drug-resistant TB (28), a new blood test for latent TB infection based on the detection of gamma-interferon (29), and serodiagnosis based on a combination of purified mycobacterial antigens (30,31) are under investigation. DNA fingerprinting methods (e.g., restriction fragment length polymorphism [RFLP] analysis) have been used to identify M. tuberculosis strains implicated in outbreaks and laboratory contamination events, and the role of these methods in detecting ongoing community TB transmission is being assessed (32).
Slower progress is being made in TB drug development, although recent advances have been made in understanding the mechanisms of drug action and antibiotic resistance. These advances are contributing to the identification of novel drug targets and the development of new classes of therapeutic agents. NIH has increased support for TB drug discovery, providing for in vitro screening and animal testing of new compounds and evaluating promising therapeutic interventions in Phase I/II studies through the Tuberculosis Research Unit. In 1997, CDC established the TB Trials Consortium (TBTC) to undertake clinical trials of new drugs for treatment and prevention in the United States. TBTC provided data that helped the U.S. Food and Drug Administration (FDA) approve rifapentine in 1998, the first new TB drug approved in more than 25 years (33). Clinical trials of short-course treatment of latent TB infection supported by NIH and CDC led to CDC recommendations for the use of a 2-month regimen of rifampin and pyrazinamide as an alternative to longer courses of isoniazid (34,35). Despite the need for new drugs, few pharmaceutical companies are involved in TB drug development (36).
A major research effort is also directed toward developing new TB vaccines. In its recent statement calling for the development of a new TB vaccine, ACET reviewed research progress in this area (4). The successful cloning of the complete genome of M. tuberculosis should accelerate vaccine development (37), and several candidate vaccines should be available for human testing within the next few years. In 1998, NIH's National Institute for Allergy and Infectious Diseases (NIAID), CDC's National Vaccine Program Office (NVPO), and ACET issued the Blueprint for Tuberculosis Vaccine Development (5), which concluded that a safe and protective TB vaccine could be developed, but that the effort required a sustained commitment (i.e., 20 years and approximately $800 million) and international, as well as public- and private-sector collaboration.
TB ELIMINATION REVISITED AND REAFFIRMED
Since ACET's TB elimination plan was published in 1989, other groups of experts have analyzed the prospects for TB elimination and eventual eradication. The Office of Technology Assessment of the U.S. Congress studied TB in the United States in the early 1990s and concluded that "with an estimated one third of the world's population infected with TB and the relative mobility of people in and out of the United States through immigration and tourism, the complete eradication of tuberculosis from this country is unlikely in the foreseeable future" (38). The International Task Force for Disease Eradication conducted an evaluation of eradicable diseases and listed TB among those diseases that are not now eradicable, citing a need "for more accurate, rapid diagnostic tests, shorter and less expensive therapies, better case findings in persons at risk, and a safer, more effective vaccine" (39).
Based on these observations, ACET reevaluated the feasibility of TB elimination in the United States and acknowledged that limitations in available tools for diagnosis, surveillance, and intervention are major barriers to disease elimination. In 1998, ACET called for a concerted and sustained national effort to develop an effective new TB vaccine, stating that "without a breakthrough in intervention strategy (i.e., a new TB vaccine), the global toll of TB will not be reduced substantially nor will the disease be eliminated in the United States" (4).
Approximately 18,000 new TB cases occur annually in the United States, and approximately 15 million persons have latent TB infection with the attendant risk for future disease. Costly TB outbreaks continue to occur, and MDR TB continues to spread. Despite recent progress, 43 states and the District of Columbia reported at least one MDR TB case during 1993-1997 (40). As a result, the annual cost of TB in the United States approaches $1 billion (41).
TB is a serious health problem that disproportionately affects disenfranchised persons. The existence of widespread racial and ethnic disparities in the incidence of TB in the United States demonstrates the need for more effective control, as well as for public policies that address the underlying causes of health disparities (42). An initiative to eliminate TB in the United States could help reduce the disease worldwide and serve as an example to other nations that recognize both the social and economic benefits of reducing the TB burden.
Despite obstacles, ACET reaffirms its commitment to eliminating TB in the United States. ACET encourages CDC to continue work initiated with the National Academy of Sciences' Institute of Medicine to review additional science and policy strategies that could aid this goal. Sustained commitment from the nation's scientific establishments is also required, and effective partnerships that extend beyond traditional TB-control alliances will be indispensable. ACET urges further strengthening of the TB-control infrastructure in the United States to apply the aggressive measures that proved effective in reducing TB cases in the 1990s. ACET also recommends the development of new diagnostic, therapeutic, and preventive tools, the most important of which is a new, effective vaccine.
To move from TB control to TB elimination in the United States, existing efforts must be sustained and enhanced, and new and improved diagnostic, treatment, and prevention methods, including a new vaccine, must be developed and applied. Support for these activities should be broad-based and include the establishment of new partnerships. TB elimination in the United States also will require recommitting to the global battle against the disease.
Tailor Prevention, Control, and Elimination Strategies Based on Local Epidemiology
The prevention, control, and elimination strategies of TB programs in the United States must be tailored to the local or regional epidemiology of TB. Several concurrent epidemics are occurring across the United States and within individual states. Incidence rates vary, as does the quality of control programs. Some low- and medium-incidence states have high-incidence rates in certain local communities, and high-incidence states are likely to have some areas of low incidence. Identifying the spectrum of TB morbidity and the status of TB control within communities, as well as the changes in these over time, allows for variations in interventions (i.e., TB-control efforts in some areas and TB-elimination strategies in others), with resources reallocated as needed. ACET recommends the following steps to enhance local TB control:
Establish New Strategic Partnerships and Reach New Stakeholders
Enhancing prevention and control efforts and eliminating TB will require new strategic partnerships to more effectively reach persons at risk for infection and to broaden the base of support for elimination. ACET recommends the following steps to achieve this goal:
Enhance the Use of Current Tools for TB Prevention and Control
Existing TB prevention and control tools have helped reduce morbidity in many parts of the United States. But closer examination of surveillance and program evaluation data reveals missed opportunities and areas for improvement. Although completion of therapy rates have improved, therapy is often prolonged, which is an inefficient use of staff time and resources. Substantial proportions of infected contacts do not start treatment or do not complete treatment, hindering efforts to prevent future TB cases. The large number of persons in the United States with latent TB infection and the high prevalence of TB infection among immigrants will continue to produce new cases of active TB unless effective strategies are better applied. Strategies that target groups at high risk for TB infection and treat those infected have often been poorly applied. Deficiencies in the quality and completeness of surveillance data also will hinder the ability of TB programs to develop effective elimination plans. Sharpening the effectiveness of existing tools can accelerate the recent progress in TB prevention and control. ACET recommends the following steps to achieve this goal:
Develop New Tools for Elimination
Although improving the application of current tools can enhance TB prevention and control efforts, new technologies must be developed, then quickly and appropriately implemented to accelerate the decline and elimination of TB. An effective vaccine would have the greatest impact on controlling and ultimately eliminating TB. Better diagnostic and treatment methods are needed to improve the accuracy, speed, and effectiveness of existing diagnostic and treatment measures. This country's research program must be expanded to capitalize on past investment and progress and to develop needed new tools. ACET recommends the following steps to achieve this goal:
Recommit to the Global Battle Against TB
The interdependence of global TB and TB in the United States necessitates that the United States make a firm commitment to the global battle against TB. The United States has an important role in fostering international collaborations to address this problem, and TB elimination efforts in this country could yield tools to improve the effort worldwide. ACET recommends the following steps to achieve this goal:
Support Broad-Based Efforts for TB Prevention and Control at National, State, and Local Levels
The efforts of public health providers alone were unable to prevent "dwindling resources for TB prevention and control in the early 1970s [which] promoted the decay of local TB control programs and set the stage for the disease's subsequent resurgence" (12). Leaders from other public health fields (e.g., HIV and sexually transmitted disease [STD] prevention, cancer control, and violence prevention) have encouraged the development of coalitions to achieve health promotion and disease prevention objectives. In this context, a coalition consists of persons who represent diverse organizations and constituencies and who agree to work together to achieve a common goal (44). Coalitions offer several advantages, including diversity of expertise and perspective, a capacity to mobilize public support, and a potential to improve trust among groups that might otherwise be in competition. Similar mobilization of new and nontraditional partners (e.g., managed care organizations) into TB coalitions is needed to broaden the base of support for TB elimination.
Strong advocacy for sustaining TB control and proceeding with TB elimination at the local, state, and national levels is also necessary to ensure the commitment of public support. To prevent another resurgence and to continue the present trend of decreasing TB morbidity, the support needed to effectively apply existing tools and strategies for prevention and control must be maintained. As morbidity declines, finding and treating cases of TB disease and latent infection could become less cost-effective and will rely more on health-care providers outside TB-control programs and health departments. Additional resources are needed for full implementation of effective elimination strategies, for biomedical research to develop the tools required for TB elimination, and for efforts to control global TB. Achieving TB elimination also will require the strategic use of mass media to promote TB elimination as an important public policy issue and advance it as a public policy initiative. ACET recommends the following steps to achieve this goal:
Since ACET issued its strategic plan for TB elimination in the United States in 1989, major changes have occurred in the epidemiology of TB and in the organization and delivery of medical and public health services in the United States. A TB resurgence was successfully curtailed, which demonstrated that investing in a strong public health infrastructure at the national, state, and local levels could have an impact on TB morbidity. The extent of the global TB epidemic and its increasing impact on TB morbidity in the United States also were recognized. Although TB in the United States can be contained by appropriate application of control methods, these events demonstrate that TB elimination will require substantial technological advancements in diagnosis, treatment, and prevention, including development of an effective vaccine. The dynamic global nature of TB also demands that control efforts abroad be enhanced to aid elimination in the United States.
Thus, ACET reaffirms its commitment to TB elimination in the United States. Many of the components needed to move from control to elimination are in place -- a proven public health infrastructure, effective standards of clinical and public health practice, a coherent blueprint for TB education, and a framework for TB and vaccine research. ACET calls for the establishment of new partnerships and coalitions to develop and support the resources and national consensus necessary to achieve TB elimination. An effective and sustained TB-elimination campaign in the United States could energize burgeoning international efforts to control TB worldwide and allow the United States to assume a leadership role in this global struggle.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to email@example.com.
Page converted: 8/10/1999
This page last reviewed 5/2/01